SequelSEC

BioCardia, Inc. BCDA

Biological Products, (No Diagnostic Substances) · CIK 0000925741 · Fiscal year ends 1231

Revenue
$0
Fiscal year ended 2025-12-31
Operating income
-$8.28M
Fiscal year ended 2025-12-31
Free cash flow
-$7.44M
Fiscal year ended 2025-12-31

BioCardia, Inc. (BCDA) reported revenue of $0 and net income of -$8.23M for the fiscal year ended 2025-12-31. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from BioCardia, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

BioCardia, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-31
Revenue$0
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$8.28M
Net income-$8.23M
Research & development$4.96M
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expense$0
Diluted EPSUnavailable
Selling, general & administrative$3.32M
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

BioCardia, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-31
Cash & equivalents$2.50M
Total assets$3.41M
Current assets$2.73M
Total liabilities$2.52M
Current liabilities$2.43M
Total equity incl. NCI$895.00K
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivable$20.00K
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$641.00K

Cash flow

BioCardia, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-31
Operating cash flow-$7.44M
Capital expenditures$7.00K
Investing cash flow-$7.00K
Financing cash flow$7.57M
Net change in cash$125.00K
Stock-based compensation$430.00K
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$24.00K

Derived

BioCardia, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-31
Free cash flow-$7.44M
Gross marginUnavailable
Operating marginUnavailable
FCF marginUnavailable
SBC / revenueUnavailable
Current ratio1.12x
Revenue YoY growth-100.0%
Net marginUnavailable
R&D / revenueUnavailable
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open BCDA in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-12View SEC filing
10-Q · Filed 2026-05-15View SEC filing
10-K · Filed 2026-03-24View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q/A · Filed 2025-10-29View SEC filing
10-Q · Filed 2025-08-11View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.